--- title: "Nasdaq to delist Glucotrack shares after bid price exception ends" url: "https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-28" section: "Listings" tickers: "NASDAQ:GCTK" source: "https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/form8-k.htm" summary: "Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at" --- By the aibio.space news desk. Sources - [Glucotrack, Inc. 8-K (2026-10-29)](https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/form8-k.htm) - [Glucotrack, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1506983/000149315226013656/) [GCTK](https://aibio.space/companies/glucotrack/) 2026-10-28 # Nasdaq to delist Glucotrack shares after bid price exception ends Tickers [GCTK](https://aibio.space/companies/glucotrack/) Nasdaq's Hearings Panel determined to delist Glucotrack common stock after its closing bid price was $0.87 on October 14, 2026, and trading is suspended at the open on October 30, 2026. ## Key facts - **Company**: Glucotrack, Inc. (NASDAQ: GCTK) - **News type**: Listings - **Primary source**: [Glucotrack, Inc. 8-K (2026-10-29)](https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/form8-k.htm) *The Capitol dome against a blue sky. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* ## The notice On October 28, 2026, Glucotrack, Inc. (NASDAQ: [GCTK](https://aibio.space/companies/glucotrack/)) received written notice from the Nasdaq Hearings Panel that it had determined to delist the company's securities. The company disclosed the notice in a Form 8-K dated October 28, 2026 and signed on October 29, 2026. The filing is made under Item 3.01 of Form 8-K, which covers notices of delisting or failure to satisfy a continued listing rule. The company is incorporated in Delaware, and its principal executive offices are at 301 Route 17 North, Suite 800, Rutherford, New Jersey 07070. The report is signed by Erik Emerson, Chief Executive Officer. The securities covered by the notice are the company's common stock, par value $0.001 per share, which is registered under the symbol GCTK on The Nasdaq Stock Market LLC. Trading in the company's common stock on Nasdaq will be suspended at the open of trading on October 30, 2026. The company expects Nasdaq to file a Form 25 with the SEC to delist its securities from Nasdaq and to deregister them under Section 12(b) of the Securities Exchange Act of 1934. ## Why the panel acted As previously disclosed, the company received a determination from Nasdaq to delist its securities for failure to meet the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), which the filing calls the Bid Price Rule. After a hearing, the Hearings Panel granted an exception to regain compliance with that rule. The exception was conditioned, among other things, on the company maintaining a closing bid price of at least $1.00 for each trading day through November 9, 2026. The filing says the panel's notice of October 28, 2026 followed a closing bid price of $0.87 on October 14, 2026. Because of that figure, the company did not satisfy the terms of the exception, the filing says. ## What happens next The company said it expects and plans for its shares to be quoted by the OTC Markets Group, Inc. once trading on Nasdaq is suspended. It also intends to apply for its securities to trade on the OTCID Market, a tier of OTC Markets. The filing's forward-looking statements section names the company's expectation that it will commence trading on the OTCID tier. The filing refers readers to the risk factors in the company's annual report on Form 10-K, filed with the SEC on March 30, 2026, for the factors that could cause actual results to differ from those expressed in forward-looking statements. ## Financial position The annual report filed March 30, 2026 shows research and development expense of $9.8 million for 2025, compared with $9.5 million for 2024. It reports a net loss of $19.4 million for 2025 and $22.6 million for 2024. Cash used in operations was $15.2 million for 2025 and $12.5 million for 2024. The quarterly report filed August 14, 2026 shows year-end 2025 cash and cash equivalents of $7.4 million, and the annual report shows year-end 2024 cash and cash equivalents of $5.6 million. The quarterly report filed August 14, 2026 shows cash and cash equivalents of $1.1 million at June 30, 2026. ## The risks ahead Glucotrack loses its Nasdaq listing at the open of trading on October 30, 2026. The shares closed at $0.87 on October 14, below the $1.00 the panel required, and the exception ran until November 9. The filing sets no date for OTC quotation or for a decision on its OTCID application, and the company only says it expects and plans to be quoted and intends to apply. The cash position is weak. Cash and cash equivalents were $1.1 million at June 30, 2026, down from $7.4 million at the end of 2025, against cash used in operations of $15.2 million for 2025 and a 2025 net loss of $19.4 million. The filing does not say how the company will fund operations after the delisting. It points readers to the risk factors in the annual report for what could change its expectations. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story GCTK Glucotrack, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Milestone Pharmaceuticals falls below Nasdaq's $1.00 minimum bid rule](https://aibio.space/news/milestone-pharmaceuticals-falls-below-nasdaqs-1-00-minimum-bid-rule/) Oct 28, 2026 --- Source page: https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nasdaq to delist Glucotrack shares after bid price exception ends", 2026-10-28, https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/